Clinical Trials Logo

Head and Neck Cancer clinical trials

View clinical trials related to Head and Neck Cancer.

Filter by:

NCT ID: NCT01506427 Withdrawn - Clinical trials for Head and Neck Cancer

A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

Start date: September 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after [F-18] HX4 injection. This study will provide guidance for future studies involving [F-18]HX4 in cancer patients.

NCT ID: NCT01427205 Withdrawn - Clinical trials for Head and Neck Cancer

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Start date: June 2013
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the addition of OSI-906 to cetuximab can improve response. The safety of these drugs will also be studied. Objectives: Primary Objective(s): To assess progression-free survival (PFS) among patients with head and neck squamous cell carcinoma (HNSCC) treated with a combination of cetuximab plus OSI-906 and compare it with PFS among patients treated with cetuximab plus placebo. Secondary Objective(s): - To assess the safety and toxicity of these treatment regimens. - To assess the efficacy of these two treatment regimens in terms of overall survival, response rate, and disease control rate - To assess the efficacy of single agent OSI-906 following cetuximab treatment in terms of response rate and disease control rate in patients who cross-over from Arm B to receive single-agent OSI-906 - To explore blood-based and tissue biomarkers

NCT ID: NCT01345084 Withdrawn - Clinical trials for Head and Neck Cancer

Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab

NICAP
Start date: November 2013
Phase: Phase 3
Study type: Interventional

Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups. Secondary: to compare the progression-free survival, incidence of locoregional failure, site of the first recurrence/progression, objective response rate assessment, quality of life assessment and incidence of adverse events.

NCT ID: NCT01326468 Withdrawn - Clinical trials for Head and Neck Cancer

Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer

Start date: January 2011
Phase: N/A
Study type: Interventional

Patients with advanced head and neck cancer is at high risk of recurrence at the primary site or in the neck. Part of normal treatment is to treat such patients with chemotherapy and radiation. The chemotherapy can include Erbitux. The purpose of this study is to treat such patients with an additional agent, Torisel. This study tests the doses of Torisel that can be safely administered together with radiation and chemotherapy.

NCT ID: NCT01312493 Withdrawn - Clinical trials for Head and Neck Cancer

Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This is a non-randomized phase II study of targeted radiotherapy (RT) administered concurrently with panitumumab in patients with locally advanced squamous carcinoma of the head and neck.

NCT ID: NCT01184027 Withdrawn - Surgery Clinical Trials

Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment

Start date: October 2010
Phase: N/A
Study type: Observational

Weight loss resulting from poor food intake is common in head and neck cancer patients. Currently, feeding tubes are placed before starting treatment to provide nutrition and prevent weight loss. However, studies have not always shown that feeding tubes prevent weight loss. Also, limiting food intake by mouth may lead to swallowing problems. The aim of this study is to compare the effect of diet and swallowing therapy with feeding tube placement. In this study, your weight, food intake, swallowing ability, and side-effects of treatment will be monitored before, during, and 3 and 6 months after treatment to see if there is any difference between the therapy groups. The investigators hope that with the addition of diet and swallowing therapy during treatment that we can improve food intake and swallowing ability while still maintaining weight.

NCT ID: NCT01142414 Withdrawn - Clinical trials for Head and Neck Cancer

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence

Start date: n/a
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether chemotherapy given together with radiation therapy is more effective with or without panitumumab in treating patients with advanced cancer of the hypopharynx, oropharynx, larynx, or oral cavity. PURPOSE: This randomized phase III trial is studying chemotherapy given together with radiation therapy to see how well it works compared with chemotherapy and radiation therapy given together with panitumumab in treating patients who have undergone surgery for advanced hypopharyngeal cancer, oropharyngeal cancer, laryngeal cancer, or oral cavity cancer at high risk of recurrence.

NCT ID: NCT01124500 Withdrawn - Clinical trials for Head and Neck Cancer

Transdermal Methylphenidate for Cancer-Related Fatigue

Start date: May 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effects, good and/or bad, of the Methylphenidate patch and a placebo patch (a patch that contains no medicine) on patients and their fatigue caused by cancer or by cancer treatment. The Methylphenidate patch contains a medication that is known to increase alertness and wakefulness. Oral methylphenidate has been used in the past to treat cancer related fatigue and is often used to treat unusual sleepiness. But this is the first time that the patch form is offered to try treating cancer fatigue in patients who cannot always swallow tablets.

NCT ID: NCT00951470 Withdrawn - Clinical trials for Head and Neck Cancer

Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema

Start date: October 2012
Phase: N/A
Study type: Interventional

Objectives: Specific Aim 1: Estimate the prevalence of head and neck lymphedema in patients who have been treated with surgery and/or radiation therapy (± chemotherapy) for oral cavity and oropharyngeal cancer. Compare functional outcomes in patients with and without lymphedema using cross-sectional survey methods. Specific Aim 2: Evaluate the effect of Complete Decongestive Therapy (CDT) provided in an outpatient setting or a home-based program in reducing lymphedema in patients previously treated with surgery and/or radiation therapy (± chemotherapy) for oral cavity and oropharyngeal cancer at 1, 3 and 6 months follow-up. Patient characteristics, treatment variables, and the health care environment will be analyzed as possible explanatory variables that influence the effect of lymphedema treatment. Specific Aim 3: Evaluate the effect of lymphedema treatment on symptom burden, self-image, and functional performance status in patients previously treated with surgery and/or radiation therapy (± chemotherapy) for oral cavity and oropharyngeal cancer.

NCT ID: NCT00937417 Withdrawn - Breast Cancer Clinical Trials

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Start date: September 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vandetanib together with docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vandetanib given together with docetaxel in treating patients with advanced solid tumors.